We are live on ! Find out more
BCM

BML Capital Management Portfolio holdings

AUM $156M
1-Year Est. Return 129.82%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$11M
Cap. Flow
+$10.3M
Cap. Flow %
8.9%
Top 10 Hldgs %
67.62%
Holding
35
New
10
Increased
4
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
SGOV icon
iShares 0-3 Month Treasury Bond ETF
SGOV
+$12.5M
2
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$9.16M
3
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
+$5.11M
4
EMBK
Embark Technology, Inc. Common Stock
EMBK
+$4.73M
5
ORMP icon
Oramed Pharmaceuticals
ORMP
+$4.31M

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$11M
2
ANF icon
Abercrombie & Fitch
ANF
+$7.66M
3
IRON icon
Disc Medicine
IRON
+$6.5M
4
VRCA icon
Verrica Pharmaceuticals
VRCA
+$5.81M
5
RELL icon
Richardson Electronics
RELL
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 53.31%
2 Consumer Discretionary 14.79%
3 Technology 5.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIL icon
1
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
$18.4M 15.87%
200,000
+100,000
+100% +$9.16M
SGOV icon
2
iShares 0-3 Month Treasury Bond ETF
SGOV
$97.5B
$12.6M 10.87%
+125,000
New +$12.5M
TLYS icon
3
Tilly's
TLYS
$121M
$8.9M 7.7%
1,154,844
– –
ANF icon
4
Abercrombie & Fitch
ANF
$4.23B
$8.21M 7.09%
295,778
-275,339
-48% -$7.66M
CYT
5
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$5.73M 4.95%
+3,146,296
New +$5.11M
PRDS
6
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$5.26M 4.55%
3,986,577
-881,407
-18% -$1.44M
ADVM
7
DELISTED
Adverum Biotechnologies
ADVM
$5.07M 4.38%
706,718
– –
CLYM
8
Climb Bio
CLYM
$727M
$4.81M 4.16%
1,658,170
-166,964
-9% -$573K
LONA
9
LeonaBio Inc
LONA
$67.8M
$4.66M 4.03%
186,491
+115,015
+161% +$3.7M
ELVN icon
10
Enliven Therapeutics
ELVN
$3.8B
$4.65M 4.02%
212,179
-542,265
-72% -$11M
STSA
11
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$4.5M 3.89%
6,440,000
– –
IRON icon
12
Disc Medicine
IRON
$2.91B
$4.41M 3.81%
208,161
-291,839
-58% -$6.5M
TRML
13
DELISTED
Tourmaline Bio
TRML
$3.63M 3.14%
+192,948
New +$3.18M
EMBK
14
DELISTED
Embark Technology, Inc. Common Stock
EMBK
$3.61M 3.12%
+1,285,390
New +$4.73M
MTCR
15
DELISTED
Metacrine, Inc. Common Stock
MTCR
$3.52M 3.04%
6,167,458
– –
ORMP icon
16
Oramed Pharmaceuticals
ORMP
$165M
$2.96M 2.56%
+1,355,925
New +$4.31M
ASTC icon
17
Astrotech Corp
ASTC
$15.5M
$2.35M 2.03%
220,410
– –
JNCE
18
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.01M 1.74%
+1,087,961
New +$1.35M
FBRX icon
19
Forte Biosciences
FBRX
$1B
$1.75M 1.51%
69,403
+10,948
+19% +$275K
ORKA
20
Oruka Therapeutics
ORKA
$5.59B
$1.41M 1.22%
58,911
-12,610
-18% -$332K
CARM
21
DELISTED
Carisma Therapeutics
CARM
$1.28M 1.1%
411,398
– –
RVP icon
22
Retractable Technologies
RVP
$20.5M
$1.17M 1.01%
668,575
– –
VRCA icon
23
Verrica Pharmaceuticals
VRCA
$96M
$975K 0.84%
15,000
-96,061
-86% -$5.81M
SRZN icon
24
Surrozen
SRZN
$255M
$899K 0.78%
+99,602
New +$1.21M
MIST icon
25
Milestone Pharmaceuticals
MIST
$148M
$867K 0.75%
220,000
+40,000
+22% +$146K
1
2

Similar funds

AIS
Accredited Investor Services St. Cloud, Minnesota $156M AUM 21.61% 1-Year Est. Return
BWM
BNB Wealth Management Silver Spring, Maryland $156M AUM
TI
Truxt Investmentos Rio De Janeiro, Brazil $156M AUM
CFG
Cornerstone Financial Group Omaha, Nebraska $156M AUM 12% 1-Year Est. Return
IWA
Invera Wealth Advisors Bend, Oregon $156M AUM 22.76% 1-Year Est. Return
PFO
Pioneer Family Office North Miami Beach, Florida $156M AUM
HCWM
Hidden Cove Wealth Management Bainbridge Island, Washington $156M AUM 16.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

BML Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, BML Capital Management held 35 positions worth $116M, up 11% from $105M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

BML Capital Management deployed $10.3M of net new capital in Q1 2023, opening 10 new positions and adding to 4 existing holdings. Its largest new stake was iShares 0-3 Month Treasury Bond ETF: 125,000 shares worth $12.6M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 65% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Enliven Therapeutics, an estimated $11M trimmed.

  • BML Capital Management's largest Q1 2023 buy was iShares 0-3 Month Treasury Bond ETF: 125,000 shares worth $12.6M.
  • BML Capital Management added most to State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q1 2023, an estimated $9.16M increase.
  • BML Capital Management's biggest Q1 2023 reduction was Enliven Therapeutics, cutting an estimated $11M.
  • BML Capital Management fully exited Richardson Electronics in Q1 2023, selling an estimated $2.03M.
  • BML Capital Management's ten largest holdings make up 68% of its $116M portfolio in Q1 2023.
  • BML Capital Management opened 10 new positions and closed 4 in Q1 2023.
  • BML Capital Management's portfolio value rose 11% quarter-over-quarter to $116M.

Based on BML Capital Management's 13F filing for Q1 2023, filed 14 Apr 2023.